What weight loss injections actually do to your body

The first weeks: your stomach and brain begin to change

Imagine it's day three of your first pen. You've eaten half your usual lunch and genuinely don't want the rest. That's not coincidence, it's the medicine doing what it was designed to do. Both tirzepatide and semaglutide slow gastric emptying, which means food sits in your stomach for longer after a meal. The physical feeling of fullness arrives sooner and lasts further into the afternoon.

At the same time, these medicines act on GLP-1 receptors in the brain's appetite-control centres, dialling down the intensity of hunger signals before a meal even arrives. Tirzepatide goes a step further, also activating GIP receptors, making it the only dual-agonist medicine of its kind currently licensed in the UK for weight management. The NHS describes this mechanism clearly in its patient information on tirzepatide.

The early weeks often bring gastrointestinal responses (nausea, occasional looser stools, or constipation) because the gut is adjusting to slower motility. For most people these settle within a couple of weeks. Staying hydrated, eating smaller portions and avoiding very fatty meals helps considerably. If you're unsure what to call the weight loss injection you've been prescribed, whether it's Mounjaro, Wegovy or something else, knowing the name helps when discussing your treatment with a clinician. What happens in your body during this phase also explains why what you eat on weight loss injections matters more than many people expect when they start.

Weeks four to twelve: what steady treatment does to appetite and metabolism

A question our prescribers hear most weeks goes something like: "Am I supposed to feel this un-hungry?" The answer is yes, and it's the point. As the dose titrates upward under prescriber guidance, the appetite suppression deepens. People often report that food preoccupies their thoughts less, not because they are forcing themselves to think about other things, but because the hormonal signals driving that preoccupation are quieter.

Insulin sensitivity typically improves alongside weight loss, particularly relevant for people with prediabetes or type 2 diabetes. Blood-pressure readings often fall gradually as body weight reduces. These aren't separate benefits bolted on, they follow from the same physiological cascade. The SURMOUNT-1 trial, involving 2,539 adults, found average body-weight reductions of around 20–21% at the 15mg tirzepatide dose over 72 weeks, according to data published in the New England Journal of Medicine. Those aren't outlier results from a handful of participants, they reflect the trial's central finding across thousands of people.

Muscle mass can reduce alongside fat during calorie restriction, which is why protein intake and resistance activity matter during treatment. A prescriber or dietitian can give you a personal steer; the general principle is that the body loses what it uses least, so keeping active preserves lean tissue. You can read more about how the body responds to weight loss injections over time.

Longer-term: what changes and what stays the same

After several months of treatment, the changes that have accumulated in your body go beyond the number on the scale. Visceral fat (the metabolically active fat stored around organs) tends to reduce meaningfully with GLP-1 treatment, which is thought to drive improvements in blood-pressure, liver markers and inflammatory indicators. These are changes that take months to accumulate and are part of why the full picture of what weight loss injections do extends well past aesthetic changes.

It's also worth being honest about what the medicines don't permanently alter. They work while you take them. The gut-hormone signalling that was suppressed gradually returns if treatment stops, and appetite typically increases again. This is biology, not a failure of effort. NICE's guidance on tirzepatide, TA1026, reflects the understanding that sustained treatment is needed for sustained effect, which is why clinical review at each repeat, rather than automatic renewal, matters.

Side effects deserve honest mention here too. The MHRA issued guidance in January 2026 highlighting acute pancreatitis as an infrequent but serious known risk with GLP-1 medicines. Severe, persistent stomach pain that radiates to the back (with or without vomiting) should prompt urgent medical attention. Gallbladder symptoms, significant dehydration from GI illness, and signs of allergic reaction are other reasons to seek help promptly. You can report suspected side effects at the MHRA's Yellow Card scheme. None of this should alarm people who are well-informed and clinically supervised; it underlines why ongoing prescriber oversight is part of the treatment, not a bureaucratic add-on.

If you're thinking about whether treatment is appropriate for you, understanding the weight and clinical criteria is a good starting point before a consultation. And if you're further along and wondering how to access treatment through a regulated route, the process for getting weight loss injections through a GPhC-registered pharmacy is covered separately. When you're ready, you can check your eligibility with our prescribers, no waiting list, same-day clinical review.